First, the protective effect of serum IPA in T2D may be achieved through its efficacy in regulating the secretion of incretin, particularly glucagon-like peptide (GLP)-1 release by intestinal endocrine L cells (64). The gene discussed is GCG; the disease is type 2 diabetes mellitus.